Patient Rating:

4.7 out of 5

149 Patient Ratings
20 Patient Comments

Djordje Atanackovic, M.D.

Patient Rating:

4.7 out of 5

149 Patient Ratings
20 Patient Comments

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address

Specialties

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions Hematology/BMT
Board Certification Hamburg Medical Council (Sub: Oncology/Hematology)

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.8
My confidence in care provider
4.7
Time care provider spent with me
4.7
Care provider spoke using clear language
4.7
Care provider's effort to include me in decisions
4.7
Care provider's concern for questions & worries
4.7
Care provider's explanation of condition/problem
4.7
Wait time at clinic
3.8
Care provider's friendliness and courtesy
4.7

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

January 29, 2015

Dr A explains things so anyone can understand. He is the best.

January 24, 2015

Dr. A is wonderful doctor. He is caring, concerned and very professional..

January 09, 2015

I have told every one I know "huntsman is the best

November 08, 2014

Was a very good experience, changes in treatment were made and explained why and what was to be expected in the near future.

October 23, 2014

The care providers are exceptional. In my case, I have a hard time remembering things and following the conversation and we had asked that my wife be present when the PA talks with me. It never fails that the PA arrives when my wife has stepped out of the room. I've asked that she be found before conversations, but things seem to go on without her. Then everything is delivered 2nd hand and not necessarily with our questions answered. I just can't follow a conversation or remember the questions that need asking.

October 20, 2014

Care provider was new at this particular position; I was the first patient she treated in her new position. Though a little uncertain about the protocol to follow she consulted with colleagues and did fine.

October 18, 2014

excellent service

October 12, 2014

I was very pleased and felt very assured about my diagnosis and prognosis. Dr. A was able to explain difficult test results in a way I could understand and reassure me of the diagnosis and prognosis that I found very comforting.

September 18, 2014

My eye was examined and deemed to be healing with no special treatment needed and I was told the tests ordered last week (Echo gram and EKG) were normal.

September 06, 2014

great job

July 18, 2014

this was my first visit with Dr Atanackovic - he was excellent

July 01, 2014

Did an excellent job.

June 25, 2014

systems problems were getting better for a while but things seem to be going downhill in terms of confusion amongst staff, wait times.

June 21, 2014

I always have fun with my bone Marrow Biopsies, after the third aspiration I raise my head and say "May I have another". This time the PA decided to do another aspiration and she was singing and I was pretending to snore. The assistant told me it was a very unique and entertaining procedure. I like to make people laugh!

June 16, 2014

Expected pain from Bone Marro Biopsy but she did an excellent job and the pain was barely noticible.

May 22, 2014

Excellent care by all who treated me that day.

May 20, 2014

Meeting and talking with Dr A was the first intelligent conversation we have had with a doctor since Dr Tricot left. Dr A is outstanding - knowledgeable and so willing to take time with us. We are delighted he has joined the BMT Clinic and hope he will be there for a long time. Please take good care of HIM!

May 01, 2014

dr Attanakovic (sp) had an AMAZING knowledge of his specialty!

April 28, 2014

Mary the nurse performed bone marrow biopsy, she was very good. Mary explained everything before proceeding. I will highly recommend her service.

April 26, 2014

Best of the best

Academic Profile

Research Interests

  • Diagnosis and Treatment of Patients with B-cell Lymphoma
  • Management of Lung Cancer Patients
  • Diagnosis and Treatment of Patients with Multiple Myeloma Including High-dose Chemotherapy Plus Autologous Stem Cell Transplantation

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions Hematology/BMT
Board Certification Hamburg Medical Council (Sub: Oncology/Hematology)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-3229 School of Medicine
Hematology
30 N 1900 E
Salt Lake City, UT 84132

Education

Education History

Type School Degree
Fellowship University Medical Center Hamburg-Eppendorf
Oncology/Hematology/Stem Cell Transplantation
Clinical/Research Fellow
Postdoctoral Fellowship New York branch of the Ludwig Institute for Cancer Research
Postdoctoral Fellow
Residency University Medical Center Hamburg-Eppendorf, Department of Oncology/Hematology
Internal Medicine
Resident
Professional Medical Benjamin Franklin University Hospital
Psychosomatic Medicine
M.D.
Internship University of Chicago
Internal Medicine
Intern
Internship University of California San Diego
Intern
Internship Hotel Dieu de
Surgery
Intern
Doctoral Training Free University Berlin
Medical Studies
Doctoral Training University of Hannover
Medical Studies

Publications

Selected Provider Publications

Journal Article

  1. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kroger N, Atanackovic D (2014). Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother, 63(11), 1151-62.
  2. Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW (2014). FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother, 63(11), 1189-97.
  3. Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Woll E, Ulrich A, Fischer R, Kruger C, Schuhmacher C (2014). A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer.
  4. Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS (2014). Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer, 135(5), 1142-52.
  5. Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kroger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S (2014). Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.LID - 10.1038/leu.2014.236 [doi]. Leukemia.
  6. Berdien B, Mock U, Atanackovic D, Fehse B (2014). TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther, 21(6), 539-48.
  7. Braga WM, da Silva BR, Alves VL, Bortoluzo AB, Atanackovic D, Colleoni GW (2014). Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma? Immunotherapy, 6(5), 569-75.
  8. Kroger N, Stubig T, Atanackovic D (2014). Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 20(2), 168-72.
  9. Stubig T, Badbaran AAUID- ORCID 0000-0002-9993-0886, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM, Fehse B, Kroger N (2014). 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm, 2014, 418292.
  10. Atanackovic D, Reinhard H, Meyer S, Spock S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kroger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C (2013). The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother, 9(12), 2533-42.
  11. Atanackovic D, Nowottne U, Freier E, Weber CS, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kroger N, Brunner-Weinzierl MC, Bokemeyer C, Deter HC (2013). Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders. Stress, 16(4), 421-8.
  12. Berdien B, Reinhard H, Meyer S, Spock S, Kroger N, Atanackovic D, Fehse B (2013). Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother, 9(6), 1205-16.
  13. Kroger N, Zabelina T, Klyuchnikov E, Kropff M, Pfluger KH, Burchert A, Stubig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR (2013). Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant, 48(3), 403-7.
  14. Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stubig T, Fehse B, Zander AR (2013). Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant, 19(3), 398-404.
  15. Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK, Klose H, Simon R, Pantel K, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W (2013). Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer, 79(3), 221-7.
  16. Wolschke C, Stubig T, Hegenbart U, Schonland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kroger N (2013). Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol, 41(2), 134-142.e3.
  17. Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W (2012). Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol, 25(12), 1566-73.
  18. Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kroger N (2012). Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst, 104(13), 1005-20.
  19. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kroger N, Atanackovic D (2012). Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol, 2012, 134081.

Review

  1. Atanackovic D, Luetkens T, Kroger N (2014). Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. [Review]. Leukemia, 28(5), 993-1000.
  2. Atanackovic D, Schilling G (2013). Second autologous transplant as salvage therapy in multiple myeloma. [Review]. Br J Haematol, 163(5), 565-72.
  3. Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D (2013). CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. [Review]. Lung Cancer, 80(3), 242-8.
  4. Braga WM, Atanackovic D, Colleoni GW (2012). The role of regulatory T cells and TH17 cells in multiple myeloma. [Review]. Clin Dev Immunol, 2012, 293479.

Case Report

  1. Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D (2014). Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol, 99(1), 91-4.

Letter

  1. Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kroger N, Atanackovic D (2014). Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients [Letter to the editor]. Blood Cancer J, 4, e212.
  2. Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M (2013). MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients [Letter to the editor]. Leukemia, 27(8), 1767-9.

Patent

  1. US Patent 7803382 (Pending). “Colon cancer antigen panel - The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject”. U.S. Patent No. Old LJ, Gnjatic S, Atanackovic D, Cerundolo V, Ling KL. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Atanackovic D, Luetkens T (Pending). “Diagnosis and therapy of hematological malignancies”. U.S. Patent No. U.S. Patent application 61/254852. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Atanackovic D, Krger N (Pending). “IL-16 as a target for the diagnosis and therapy of haematological malignancies and solid tumors”. U.S. Patent No. U.S. Patent application 12/716481. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Gnjatic S, Atanackovic D, Old LJ (Pending). “Isolated NY-ESO-1 peptides which bind to HLA class II molecules and uses thereof”. U.S. Patent No. U.S. Patent application 10/556853. Washington, D.C.:U.S. Patent and Trademark Office.

Clinical Trials

Video & News